GlassScriptPhysician profile
Talisha Hern
NPI 1275100703
$3,020.80
in general payments reported to CMS, 2019-2025
19 companies · $935 in 2025
The $935 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $741 · 2024: $1,081 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.64 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $542.66 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $496.07 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $272.93 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $237.31 | 2023-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $231.54 | 2023-2025 | Watchman Flx, Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $209.28 | 2022-2023 | Lokelma, Farxiga |
| Janssen Pharmaceuticals, INC | $183.62 | 2023-2024 | Xarelto |
| Pfizer INC. | $182.79 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.18 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $129.87 | 2024 | Arcalyst |
| Novo Nordisk INC | $89.74 | 2024 | |
| Glaxosmithkline, LLC. | $59.79 | 2022-2023 | Benlysta |
| Travere Therapeutics, INC. | $55.95 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $46.50 | 2022-2023 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $38.87 | 2024-2025 | Amvuttra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32.47 | 2022-2023 | Jynarque |
| Alexion Pharmaceuticals, INC. | $32.12 | 2022 | |
| Aimmune Therapeutics, INC. | $21.28 | 2025 | Vowst |
| Daiichi Sankyo INC. | $17.83 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talisha Hern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.